IPM Take
Hypertensive disorders of pregnancy are one of the clearest places where cardiovascular prevention, maternal health and health-system design collide. The medication choices are increasingly clear, but the pathway is still too fragile. Patients are often discharged into a grey zone of blood pressure checks, breastfeeding concerns, fragmented follow-up and inconsistent prescribing confidence. Safe treatment should not depend on whether an obstetrician, cardiologist, pharmacist and primary care clinician happen to be aligned. It should be built into the system.
Executive Summary
An ACC expert analysis published in July 2026 provides a practical framework for antihypertensive medication selection in pregnancy and lactation. The authors identify extended-release nifedipine and labetalol as preferred first-line oral antihypertensive medications in pregnancy. For lactation, preferred first-line oral options include extended-release nifedipine, amlodipine, enalapril and labetalol.
The guidance also clarifies several safety issues. ACE inhibitors and angiotensin receptor blockers are contraindicated in pregnancy, but selected ACE inhibitors such as enalapril, benazepril and captopril are considered preferred during lactation because of available safety data and low levels in breast milk. Atenolol is contraindicated in pregnancy and lactation because of fetal and infant safety concerns. Several second-line options, including hydralazine, hydrochlorothiazide, metoprolol, carvedilol and spironolactone during lactation, can be considered depending on the clinical situation.
The broader policy issue is urgent. Hypertension in pregnancy contributes to maternal morbidity, persistent hypertension, rehospitalisation and long-term cardiovascular disease risk. Evidence from the CHAP trial showed that treating mild chronic hypertension in pregnancy improved pregnancy outcomes compared with waiting until severe hypertension developed.
The policy conclusion is straightforward: medication safety information must be translated into reliable care pathways. That means clear protocols, discharge planning, pharmacist involvement, blood pressure monitoring, lactation-compatible prescribing, postpartum follow-up and long-term cardiovascular prevention.
Why it matters
- Policymakers and public authorities: Maternal cardiovascular safety requires more than emergency obstetric care. It needs medication access, postpartum surveillance, reimbursement and continuity across obstetrics, cardiology and primary care.
- Clinicians and providers: Pregnancy and lactation require confident, evidence-based prescribing. Over-caution can lead to undertreatment; poorly coordinated treatment can lead to preventable harm.
- Pharmacists: Medication counselling in pregnancy and breastfeeding is a critical safety function. Pharmacists should be embedded in cardio-obstetric and postpartum hypertension pathways.
- Payers and HTA bodies: Coverage should support home blood pressure monitoring, postpartum visits, medication review, care coordination and remote follow-up, not only hospital treatment after complications occur.
- Patients and advocates: Patients should not have to choose between treating hypertension and breastfeeding because of unclear advice. They need consistent information and rapid access to follow-up.
Hypertension in pregnancy is not a side issue in cardiovascular medicine. It is one of the earliest warnings that a patient may be entering a higher-risk cardiovascular life course.
Yet the system still treats too much of this care as episodic.
Pregnancy. Delivery. Discharge. A few blood pressure checks if the pathway works. Then a handoff into primary care that may or may not happen.
A new ACC expert analysis on antihypertensive medications in pregnancy and lactation is useful because it cuts through a common clinical problem: what can be prescribed safely, when, and with what caveats?
The practical message is clear. During pregnancy, extended-release nifedipine and labetalol are preferred first-line oral antihypertensive medications. In lactation, preferred first-line options include extended-release nifedipine, amlodipine, enalapril and labetalol.
That may sound like a narrow medication update. It is not.
Medication confidence is a policy issue.
If clinicians are uncertain about pregnancy or breastfeeding safety, treatment can be delayed. If patients receive contradictory advice, adherence suffers. If discharge plans are vague, blood pressure can rise after birth without rapid response. If breastfeeding is treated as a reason to avoid treatment rather than adapt it, patients are left with unnecessary fear.
The result is predictable: preventable risk travels through the cracks between specialties.
Hypertensive disorders of pregnancy are already linked to maternal morbidity, persistent hypertension, rehospitalisation and long-term cardiovascular risk. The postpartum period is especially dangerous because blood pressure can worsen after discharge, just as clinical contact becomes less frequent. This is where health systems often mistake “no longer pregnant” for “no longer at risk.”
The ACC analysis matters because it gives clinicians a clearer medication map.
Extended-release nifedipine has a well-established safety profile in pregnancy and is compatible with lactation. Labetalol is also widely used, although dosing frequency can be challenging. Amlodipine has less pregnancy data than nifedipine but is considered a useful option in lactation. Enalapril is contraindicated during pregnancy because ACE inhibitors are unsafe for the fetus, but it becomes a preferred option during lactation because breast milk transfer is low and safety data are stronger than for many alternatives.
This distinction is exactly why protocols matter.
A medicine can be inappropriate in pregnancy but appropriate after delivery. A drug can be safe in breastfeeding but still require infant monitoring. A postpartum patient may need a rapid medication change if they are breastfeeding, have kidney disease, have cardiomyopathy, or need longer-term blood pressure control.
That complexity is manageable. But only if someone owns it.
Too often, postpartum hypertension sits in a no-man’s land between obstetrics, cardiology, primary care, emergency medicine and pharmacy. The patient may not know whom to call. The primary care clinician may not have the pregnancy history. The cardiologist may not see the patient until later. The pharmacist may catch the interaction but not have access to the care plan.
That is not patient-centred care. It is a relay race with missing runners.
The evidence base has also shifted. The CHAP trial showed that treating mild chronic hypertension during pregnancy improved outcomes compared with reserving treatment until severe hypertension developed. That trial helped move the field away from older hesitation about treating non-severe chronic hypertension in pregnancy. It also reinforced a broader principle: avoiding medication is not automatically safer if uncontrolled blood pressure is doing harm.
The same logic applies postpartum. Blood pressure control after pregnancy is not administrative follow-up. It is cardiovascular prevention.
NICE guidance in the UK makes this practical by stating that antihypertensive treatment can be adapted to accommodate breastfeeding and that needing antihypertensive medication does not prevent breastfeeding. It also recommends structured postpartum blood pressure monitoring and written care plans after preeclampsia.
That should be the global direction: clarity, continuity and written responsibility.
The policy failure is not that evidence does not exist. The failure is that evidence often does not become workflow.
A serious cardio-obstetric hypertension pathway should include risk identification during pregnancy, medication selection protocols, patient-friendly counselling, discharge planning, home blood pressure monitoring, rapid titration pathways, pharmacy review and long-term cardiovascular handoff. It should not depend on the patient repeatedly explaining that they recently had preeclampsia, are breastfeeding, and were told three different things about medication safety.
There is also an equity issue.
Postpartum follow-up is harder for patients with limited paid leave, unstable insurance, low income, transport barriers, rural residence, language barriers or previous negative experiences with the health system. These are the same patients who are more likely to be harmed by fragmented care. A pathway that assumes every patient can return easily for repeated in-person checks is not an equity strategy.
Remote blood pressure monitoring can help, but only if designed properly. A home cuff without a response team is not a care model. Text-based reporting without medication titration is surveillance without treatment. Digital tools should shorten the distance between abnormal blood pressure and clinical action.
Pharmacists should also be treated as part of the solution. Pregnancy and lactation prescribing require detailed medication knowledge. Pharmacists can support dose review, adherence, breastfeeding-compatible alternatives, adverse-effect counselling and patient education. In many health systems, they are an underused bridge between discharge and follow-up.
The workforce implications are real. Cardio-obstetrics cannot be left to tertiary centres alone. General cardiologists, obstetricians, primary care clinicians, midwives, nurses and pharmacists need practical competencies around hypertension in pregnancy and postpartum. The ACC article is useful precisely because it is operational, not abstract.
But implementation will require payment reform.
Someone must be reimbursed for postpartum medication review. Someone must be paid to monitor home blood pressure data. Someone must be responsible for titration. Someone must coordinate handoff into long-term cardiovascular prevention. If this work is unfunded, the pathway will remain aspirational.
There is also a communication challenge. Patients need clear, non-alarming advice.
The message should not be: blood pressure medications are risky in breastfeeding.
The message should be: blood pressure control matters, and there are breastfeeding-compatible options.
That distinction can change adherence, trust and outcomes.
The broader cardiovascular lesson is uncomfortable. Pregnancy often reveals risk earlier than standard cardiology pathways do. Hypertension in pregnancy is not only a pregnancy complication. It is a future cardiovascular risk marker. It should trigger long-term prevention, not disappear after the postpartum window.
This means documenting hypertensive disorders of pregnancy in cardiovascular records. It means annual blood pressure follow-up. It means diabetes, kidney and lipid assessment where appropriate. It means counselling about future pregnancy risk and long-term heart health. It means treating the postpartum period as a bridge into prevention, not a discharge endpoint.
Safe antihypertensive prescribing in pregnancy and lactation is not just about choosing nifedipine, labetalol, enalapril or amlodipine.
It is about building a health system where safe choices happen reliably. Hypertension is treatable. The scandal is when the pathway is not.
